Howard Christopher L
Known title: EVP, GC and SecretaryCIK: 0001337573
Associated companies
Transaction History
| ACHC | ▲ Buy | Grant | 5,205 | $0 | 5/9/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 956 | $67K | 5/2/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 538 | $40K | 4/23/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 2,732 | $190K | 3/24/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 201,003 | $0 | 2/21/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 6,224 | $0 | 2/21/2023 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 78,823 | $6.4M | 2/21/2023 | View on chart |
| ACHC | ▼ Sell | Open Market | 12,214 | $998K | 8/8/2022 | View on chart |
| ACHC | ▲ Buy | Option Exercise | 6,137 | $311K | 8/4/2022 | View on chart |
| ACHC | ▼ Sell | Open Market | 8,443 | $688K | 8/4/2022 | View on chart |
| ACHC | ▲ Buy | Grant | 4,693 | $0 | 4/11/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 2,732 | $176K | 3/24/2022 | View on chart |
| ACHC | ▼ Sell | Gift | 8,003 | $0 | 3/3/2022 | View on chart |
| ACHC | ▼ Sell | Gift | 8,003 | $0 | 3/3/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 801 | $49K | 3/2/2022 | View on chart |
| ACHC | ▲ Buy | Grant | 51,515 | $0 | 2/25/2022 | View on chart |
| ACHC | ▼ Sell | Tax Withholding | 12,506 | $712K | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Acadia Healthcare Sets Q3 2026 Earnings Date
Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.
Acadia Healthcare Sets Q3 2026 Earnings Date. Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.